|Application ||WB, IF|
|Other Accession||P70645, P13019, Q8R016|
|Calculated MW||H=53;M=53;Rat=52 KDa|
|Other Names||BLMH;Bleomycin hydrolase|
|Target/Specificity||This BLMH antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 212-242 amino acids from the Central region of human BLMH.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||BLMH Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||The normal physiological role of BLM hydrolase is unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxamide bond of its B- aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity.|
Provided below are standard protocols that you may find useful for product applications.
The normal physiological role of BLM hydrolase is unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxamide bond of its B-aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity (By similarity).
Barrow I.K.-P., et al. Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
Ferrando A.A., et al. Cancer Res. 56:1746-1750(1996).
Broemme D., et al. Biochemistry 35:6706-6714(1996).
Kalnine N., et al. Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
Ota T., et al. Nat. Genet. 36:40-45(2004).